Immunocore (IMCR) Stock Price, News & Analysis

Company Overview

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma. Beyond this, Immunocore’s pipeline includes multiple additional ImmTAC candidates in various stages of clinical evaluation across solid tumor indications such as colorectal, lung and other metastatic cancers. The firm also pursues collaborations with major biopharmaceutical partners to expand the reach and application of its TCR technology, notably with Genentech and Fosun Pharma.

Headquartered in Oxford, England, with research and development facilities in Philadelphia, Pennsylvania, Immunocore leverages a global infrastructure to support its clinical trials and manufacturing efforts. Founded in 2008, the company is led by Chief Executive Officer Dr. Bahija Jallal, under whose direction Immunocore has advanced its first‐in‐class therapies from discovery through late‐stage clinical development. With a commitment to innovation in immune‐based medicine, Immunocore continues to explore new targets and indications that may benefit from the specificity and potency of its TCR‐based platform.

Key Stats

• Today's Range: $33.64 to $35.09
• 50-Day Range: $31.87 to $37.20
• 52-Week Range: $23.15 to $39.33
• Volume: 64,771 shs
• Average Volume: 330,349 shs
• Market Capitalization: $1.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.89
• Consensus Rating: Hold

Immunocore Stock Analysis - MarketRank™

Immunocore scored higher than 40% of companies evaluated by MarketBeat, and ranked 788th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Immunocore has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Immunocore has a consensus price target of $56.89, representing about 68.2% upside from its current price of $33.83.

Amount of Analyst Coverage

Immunocore has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunocore is -84.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunocore is -84.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunocore has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.46% of the float of Immunocore has been sold short.

Short Interest Ratio / Days to Cover

Immunocore has a short interest ratio ("days to cover") of 25.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunocore has recently decreased by 0.91%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunocore does not currently pay a dividend.

Dividend Growth

Immunocore does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.46% of the float of Immunocore has been sold short.

Short Interest Ratio / Days to Cover

Immunocore has a short interest ratio ("days to cover") of 25.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunocore has recently decreased by 0.91%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.03

News Sentiment

Immunocore has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immunocore this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immunocore insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMCR Stock Analysis - Frequently Asked Questions

How have IMCR shares performed this year?

Immunocore's stock was trading at $29.50 at the beginning of 2025. Since then, IMCR stock has increased by 14.7% and is now trading at $33.8250.

How were Immunocore's earnings last quarter?

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) issued its earnings results on Thursday, August, 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The company's revenue for the quarter was up 30.0% on a year-over-year basis.
Read the conference call transcript.

When did Immunocore IPO?

Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

Who are Immunocore's major shareholders?

Immunocore's top institutional investors include Primecap Management Co. CA (7.51%), Bellevue Group AG (4.86%), BVF Inc. IL (2.04%) and Fiera Capital Corp (1.62%). Insiders that own company stock include Bros Advisors Lp Baker and Leger Tina Amber St.
View institutional ownership trends.

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunocore own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCR
• CIK: 1671927
• Web: www.immunocore.com
• Phone: 44-12-3543-8600
• Fax: N/A
• Employees: 320
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immunocore: $56.89
• High Price Target: $100.00
• Low Price Target: $24.00
• Potential Upside/Downside: +65.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.45
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.09 million
• Net Margins: -5.70%
• Pretax Margin: -6.27%
• Return on Equity: -5.40%
• Return on Assets: -1.93%

Debt

• Debt-to-Equity Ratio: 1.01
• Current Ratio: 5.89
• Quick Ratio: 5.86

Sales & Book Value

• Annual Sales: $310.20 million
• Price / Sales: 5.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.20 per share
• Price / Book: 4.78

Miscellaneous

• Outstanding Shares: 50,390,000
• Free Float: 45,147,000
• Market Cap: $1.73 billion
• Optionable: Optionable
• Beta: 0.77